DLDouglas M. Lublin

Douglas M. Lublin

*This is an algorithmically generated author record based on publicly available information.

Douglas M. Lublin has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Universal RBCs

    by Douglas M. Lublin


  • Molecular basis of Cromer blood group antigens

    by D.M. Lublin, S. Kompelli, J.R. Storry, M.E. Reid

    BACKGROUND: The Cromer blood group system consists of 10 antigens located on decay‐accelerating factor (DAF). Previous molecular genetic analysis has determined the basis for four of these antigens. The present study was undertaken to identify the mutations that determine the remaining antigens.STUDY DESIGN AND METHOD: Existing or new data were used to localize each Cromer system antigen to a specific short consensus repeat (SCR) domain of DAF. The exon encoding that SCR domain was amplified by using the polymerase chain reaction (PCR) on genomic DNA obtained from individuals of that Cromer phenotype, and the DNA product was subjected to DNA sequence analysis.RESULTS: The Tca/Tcc polymorphism is due to an R18P amino acid substitution in SCR1 of DAF. The Es(a+)/Es(a–) polymorphism is due to an I46N mutation in SCR1 of DAF. The WESb/WESa polymorphism is due to an L48R mutation in SCR1 of DAF. The UMC+/UMC– polymorphism is due to a T216M substitution in SCR4 of DAF.CONCLUSIONS: With information from previous reports and the findings of this study, the molecular genetic basis of all known alleles of the Cromer blood group system has been elucidated. Single amino acid substitutions are responsible for 9 of the 10 antigens (all except the multiple‐epitope antigen IFC).


  • Open Access

    CD36 Is Palmitoylated on Both N- and C-terminal Cytoplasmic Tails

    by Nengbing Tao, Steven J. Wagner, Douglas M. Lublin


    • 15 August 1994
      • Vol. 84  (4) , 1276-82

    Molecular basis of reduced or absent expression of decay-accelerating factor in Cromer blood group phenotypes.

    by D M Lublin, G Mallinson, J Poole, M E Reid, E S Thompson, B R Ferdman, M J Telen, D J Anstee, M J Tanner

    The human erythrocyte blood group system Cromer consists of high-incidence and low-incidence antigens that reside on decay-accelerating factor (DAF; CD55), a glycosyl-phosphatidylinositol-anchored membrane protein that regulates complement activation on cell surfaces. In the Cromer phenotypes Dr(a-) and Inab there is reduced or absent expression of DAF, respectively. This study investigated the molecular basis of the reduced DAF expression by polymerase chain reaction amplification of genomic DNA and RNA/cDNA obtained from Epstein-Barr virus-transformed lymphoblastoid cell lines. Sequence analysis of the Inab propositus showed a single nucleotide substitution in exon 2 of the DAF gene and at the corresponding position in the cDNA, G314-->A resulting in Trp53-->Stop. This truncation near the amino terminus explains the complete absence of surface DAF in the Inab phenotype. A similar analysis was performed for two Dr(a-) individuals, including KZ, who was previously reported to be Inab phenotype but is now shown by immunochemical and serologic methods to be Dr(a-) phenotype. A single nucleotide change was found in exon 5 of the DAF gene, C649-->T resulting in Ser165-->Leu, which we had previously shown to lead to loss of the Dra epitope. However, two species of cDNA were found, one encoding full-length DAF with the single amino acid change and the more abundant species having a 44-nucleotide deletion. The 44 nucleotide deletion includes the single polymorphic site, which creates a cryptic branch point in the Dr(a-) allele that leads to use of a downstream cryptic acceptor splice site. This shifts the reading frame and leads to a premature stop codon that precludes membrane anchoring. Thus, the single point mutation in the Dr(a-) phenotype results in a novel use of alternative splicing and provides a molecular explanation for both the antigenicity and the reduced DAF expression seen in this phenotype.


    • 15 July 1993
      • Vol. 82  (2) , 651-5

    Molecular cloning of RhD cDNA derived from a gene present in RhD-positive, but not RhD-negative individuals.

    by M A Arce, E S Thompson, S Wagner, K E Coyne, B A Ferdman, D M Lublin

    The Rh blood group system plays a major role in immune and nonimmune hemolytic states. Although an Rh cDNA has been previously cloned, there is no information on which Rh antigenic protein it encodes. Using polymerase chain reaction (PCR) amplification, we have identified this original Rh clone, here designated Rh21, and an additional Rh cDNA clone, Rh13, that is 96% nucleotide- and 92% amino acid-identical to Rh21, with the substitutions scattered throughout the sequence. A molecular genetic approach was used to match this Rh clone with an Rh specificity. The mRNA transcript for Rh13 was present in reticulocytes from RhD-positive individuals, but was absent from the reticulocytes of RhD-negative individuals. Using conventional screening of genomic libraries, as well as PCR cloning, partial genomic clones for these two Rh cDNAs were obtained. Based on PCR analysis and Southern blots, the Rh21 gene was present in all individuals, but an intact Rh13 gene was only present in RhD-positive and not RhD-negative individuals. Thus, by correlating the presence of Rh mRNA and gene sequences with individual Rh phenotypes, we were able to establish that the new Rh13 cDNA clone represents the RhD protein.